參考價(jià)	￥ 1013

信號(hào)通路

MedChemExpress (M

CAS	761439-42-3	純度	99.27%
分子量	614.2	分子式	C??H??ClN?O?S
供貨周期	現(xiàn)貨	規(guī)格	10 mM * 1 mL
貨號(hào)	HY-10192	應(yīng)用領(lǐng)域	醫(yī)療衛(wèi)生,化工,生物產(chǎn)業(yè),制藥/生物制藥

NVP-TAE 684 (TAE 684) 是一種高效的，選擇性的 ALK 抑制劑，阻止 ALCL 衍生的 ALK 依賴性細(xì)胞株的生長，IC50 值為 2-10 nM。

詳細(xì)介紹

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

NVP-TAE 684

CAS No. : 761439-42-3

MCE 國際站：NVP-TAE 684

產(chǎn)品活性：NVP-TAE 684 (TAE 684) 是一種高效的，選擇性的 ALK 抑制劑，阻止 ALCL 衍生的 ALK 依賴性細(xì)胞株的生長，IC₅₀ 值為 2-10 nM。

研究領(lǐng)域：Protein Tyrosine Kinase/RTK | Apoptosis

作用靶點(diǎn)：Anaplastic lymphoma kinase (ALK) | Apoptosis

In Vitro: TAE684 inhibits the proliferation of Ba/F3 NPM-ALK cells with an IC₅₀ of 3 nM, without affecting the survival of parental Ba/F3 cells at concentrations up to 1 μM. TAE684 inhibits STAT3 and STAT5 phosphorylation in a dose-dependent manner in both Ba/F3 NPM-ALK and Karpas-299 cells. TAE684 induces apoptosis and G1 phase arrest in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines.
NVP-TAE684 markedly reduces cell survival in both sensitive H3122 and H3122 CR cells, but has little to no effect on the viability of other, non-ALK-dependent cancer cell lines. NVP-TAE684 treatment of H3122 CR cells suppresses phosphorylation of ALK, AKT, and ERK and induces marked apoptosis.
TAE684 potently suppresses the survival of Ba/F3 cells expressing the EML4-ALK L1196M mutant.
Neurite outgrowth induced by expression of the mALKR1279Q mutant is completely inhibited at 30 nM NVP-TAE684, which is comparable with the response seen with activated wt mALK.

In Vivo: NVP-TAE684 suppresses lymphomagenesis in two independent models of ALK-positive ALCL and induces regression of established Karpas-299 lymphomas. TAE684 displays appreciable bioavailability and half-life in vivo.
TAE684 (1, 3, and 10 mg/kg. p.o.) significantly delays in lymphoma development and shows 100- to 1,000-fold reduction in luminescence signal. The TAE684- (10 mg/kg) treated group appeares healthy and does not display any signs of compound- or disease-related toxicity.